15th Apr 2016 08:50
| For filings with the FCA include the annex | |||||
| For filings with issuer exclude the annex | |||||
| TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi | |||||
| 1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii | Oxford Biomedica plc | ||||
| 2 Reason for the notification (please tick the appropriate box or boxes): | |||||
| An acquisition or disposal of voting rights | √ | ||||
| An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached | √ | ||||
| An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments | |||||
| An event changing the breakdown of voting rights | |||||
| Other (please specify): | 
 | ||||
| 3. Full name of person(s) subject to thenotification obligation: iii | Aviva plc & its subsidiaries | ||||
| 4. Full name of shareholder(s) (if different from 3.):iv | Registered Holder: 
 BNY Norwich Union Nominees Limited 15,181,044* 
 Chase (GA Group) Nominees Limited 219,780,219* State Street Nominees Limited 2,159,221* 
 *denotes direct interest 
 Chase (GA Group) Nominees Limited 20,807,732 
 Chase Nominees Limited 7,566,886 
 Vidacos Nominees Limited 11,939,558 
 | ||||
| 5. Date of the transaction and date onwhich the threshold is crossed orreached: v | 12 April 2016 | ||||
| 6. Date on which issuer notified: | 14 April 2016 | ||||
| 7. Threshold(s) that is/are crossed orreached: vi, vii | 9% to 8% at Direct Interest Level (Box 8A&B) | ||||
| 8. Notified details: | |||||||||||
| A: Voting rights attached to shares viii, ix | |||||||||||
| Class/type ofshares if possible usingthe ISIN CODE | Situation previousto the triggeringtransaction | Resulting situation after the triggering transaction | |||||||||
| NumberofShares | NumberofVotingRights | Numberof shares | Number of votingrights | % of voting rights x | |||||||
| Direct | Direct xi | Indirect xii | Direct | Indirect | |||||||
| Ordinary Shares GB00066458157 
 | 283,550,521* | 283,550,521* | 277,434,660 | 237,120,484 | 40,314,176 | 8.77% | 1.49% | ||||
| 
 * Includes Right to Recall Loaned Shares (4,865,559) 
 | |||||||||||
| B: Qualifying Financial Instruments | |||||||||||
| Resulting situation after the triggering transaction | |||||||||||
| Type of financialinstrument | Expirationdate xiii | Exercise/Conversion Period xiv | Number of votingrights that may beacquired if theinstrument isexercised/ converted. | % of votingrights | |||||||
| RIGHT TO RECALL LOANED SHARES | N/A | N/A | 5,940,559* 
 *DIRECT INTEREST | 0.22% | |||||||
| C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi | ||||||
| Resulting situation after the triggering transaction | ||||||
| Type of financialinstrument | Exercise price | Expiration date xvii | Exercise/Conversion period xviii | Number of voting rights instrument refers to 
 | % of voting rights xix, xx 
 | |
| 
 
 
 | Nominal | Delta | ||||
| Total (A+B+C) | |
| Number of voting rights | Percentage of voting rights | 
| 283,375,219 | 10.48% | 
| 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi | ||
| The voting rights are managed and controlled by Aviva Investors Global Services Limited, with the following chain of controlled undertakings:- 
 Aviva Investors Global Services Limited: · Aviva plc (Parent Company) · Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc) · Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited) · Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited) 
 | ||
| Proxy Voting: | ||
| 10. Name of the proxy holder: | See Section 4 | |
| 11. Number of voting rights proxy holder will ceaseto hold: | ||
| 12. Date on which proxy holder will cease to holdvoting rights: | ||
| 13. Additional information: | Figures are based the total number of voting rights of 2,702,864,994 as per the Company's Total Voting Rights Announcement of 1 April 2016. 
 | |
| 14. Contact name: | Tim Watts | |
| 15. Contact telephone number: | 01865 783000 | |
Related Shares:
Oxford Biomedica